Morepen to Launch Resmetirom - a New Drug for Fatty Liver

Morepen Laboratories Ltd. has received clearance from the Subject Expert Committee (‘SEC’) of Central Drugs Standard Control Organization (‘CDSCO’) to conduct Bioequivalence (‘BE’) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets. This is a significant step forward in bringing a much-needed innovation to the hepatology market. Resmetirom is a promising therapy under development for non-alcoholic steatohepatitis (‘NASH’), a serious form of non-alcoholic fatty liver disease. Morepen is one of the first few Indian companies to foray into this therapeutic area and is strategically positioned to serve both domestic and international markets. The global NASH treatment market is projected to grow significantly by 2032.